AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8630719 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg bid
Number of subjects: 311
Study 8630719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 8630719 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 311
Study 8630719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 311
Study 8630719 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 311
Study 1428726 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluorodeoxycytidine (dFdC) administered by 30 minute infusion at doses of 5-90 mg/m2
Number of subjects: 50
Study 1428726 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluorodeoxycytidine (dFdC) administered by 5 minute bolus at doses of 30-150 mg/m2
Number of subjects: 50
Study 6385309 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol plus ethanol
Number of subjects: 0
Study 6385309 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam plus ethanol
Number of subjects: 0
Study 6385309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3089049 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 50
Study 3089049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 50
Study 3089049 — intervention group
Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 50
Study 29152718 — intervention group
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System (LED blue light phototherapy with photo-converter chromophores), treated hemiface, 12 weeks total (6 weeks treatment + 6 weeks follow-up)
Number of subjects: 49
Study 29152718 — intervention group
Group type: COMPARATOR
Intervention: Control hemiface (untreated during Main trial), received 6 weeks of treatment (twice weekly)
Number of subjects: 49
Study 26692004 — intervention group
Group type: EXPERIMENTAL
Intervention: Henagliflozin 5 mg/day
Number of subjects: 30
Study 26692004 — intervention group
Group type: EXPERIMENTAL
Intervention: Henagliflozin 10 mg/day
Number of subjects: 30
Study 26692004 — intervention group
Group type: EXPERIMENTAL
Intervention: Henagliflozin 20 mg/day
Number of subjects: 30
Study 26692004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25182100 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vagal nerve block device
Number of subjects: 239
Study 25182100 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 239
Study 22732370 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 14
Study 20211542 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis plus intra‐articular injection of tenoxicam
Number of subjects: 21
Study 20211542 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis alone
Number of subjects: 21
Study 19183313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin 3500 IU/day for 10 days, followed by 2500 IU/day for up to 3 months plus standard care for ulcers
Number of subjects: 70
Study 19183313 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard care for ulcers
Number of subjects: 70
Study 15914614 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral angiotensin II receptor blocker (ARB)
Number of subjects: 698
Study 15914614 — intervention group
Group type: COMPARATOR
Intervention: AGTR2/3123A genotype
Number of subjects: 698
Study 15914614 — intervention group
Group type: COMPARATOR
Intervention: AGTR2/3123C‐‐>A polymorphism
Number of subjects: 698
Study 15914614 — intervention group
Group type: COMPARATOR
Intervention: ACE/ID+DD (D carriers)
Number of subjects: 698
Study 12578433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate
Number of subjects: 10
Study 12578433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide
Number of subjects: 10
Study 12578433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10902989 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy and micronutrient supplement (1171 kJ + 12 mg iron)
Number of subjects: 136
Study 10902989 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy and micronutrient supplement (209 kJ + 12 mg iron)
Number of subjects: 136
Study 10902989 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy and micronutrient supplement (104 kJ)
Number of subjects: 136
Study 8770304 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of ketorolac administered via Jackson‐Pratt drain or intravenously
Number of subjects: 60
Study 8770304 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) administered via Jackson‐Pratt drain or intravenously
Number of subjects: 60
Study 1315652 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine supplementation
Number of subjects: 0
Study 1315652 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (Control)
Number of subjects: 0
Study 1315652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Arginine and Control)
Number of subjects: 0
Study 3907354 — intervention group
Group type: COMPARATOR
Intervention: Rocket clip
Number of subjects: 663
Study 3907354 — intervention group
Group type: COMPARATOR
Intervention: Tubal ring
Number of subjects: 663
Study 30485400 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at weeks 0 and 4 and every 8 weeks thereafter
Number of subjects: 0
Study 30485400 — intervention group
Group type: COMPARATOR
Intervention: adalimumab 80 mg at week 0, 40 mg at week 1, and 40 mg every 2 weeks thereafter
Number of subjects: 0
Study 29861315 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring insertion
Number of subjects: 0
Study 29861315 — intervention group
Group type: COMPARATOR
Intervention: Heel stick
Number of subjects: 0
Study 26861939 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of antihypertensive medication
Number of subjects: 10269
Study 26861939 — intervention group
Group type: COMPARATOR
Intervention: Evening dosing of antihypertensive medication
Number of subjects: 10269
Study 23294350 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sialogogue spray containing 1% malic acid
Number of subjects: 41
Study 23294350 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 41
Study 22270505 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope Cobalt® video laryngoscope (GCV)
Number of subjects: 60
Study 22270505 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy with a Miller blade (DL)
Number of subjects: 60
Study 20462041 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of midazolam (0.04 mg/kg)
Number of subjects: 60
Study 20462041 — intervention group
Group type: COMPARATOR
Intervention: Continuous electroacupuncture (EA) at 30‐100 Hz on Zusanli (ST36) and Sanyinjiao (SP6) acupoints
Number of subjects: 60
Study 20462041 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural infusion and EA
Number of subjects: 60
Study 18781432 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 18781432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16269640 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprotection trials
Number of subjects: 42
Study 12419082 — intervention group
Group type: EXPERIMENTAL
Intervention: sequential estradiol‐norethisterone acetate regimen
Number of subjects: 42
Study 12419082 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 10993623 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum 5-day IV antibiotic course (Group 1)
Number of subjects: 94
Study 10993623 — intervention group
Group type: COMPARATOR
Intervention: No minimum IV antibiotic requirement (Group 2)
Number of subjects: 94
Study 9011436 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcisorb
Number of subjects: 0
Study 9011436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1459376 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl isobutyl ketone (MIBK) at 100 ppm
Number of subjects: 143
Study 1459376 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl ethyl ketone (MEK) at 200 ppm
Number of subjects: 143
Study 1459376 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBK at 50 ppm with MEK at 100 ppm
Number of subjects: 143
Study 1459376 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5‐min presentation of 25 ppm MEK‐MIBK)
Number of subjects: 143
Study 1459376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol by ingestion (95%‐0.84 ml/kg)
Number of subjects: 143
Study 3976470 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group (n = 19)
Number of subjects: 156
Study 3976470 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 22)
Number of subjects: 156
Study 3976470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156
Study 31515006 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative intervention through Short Message Service (SMS)
Number of subjects: 0
Study 31515006 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 0
Study 30010751 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (200 mg twice daily)
Number of subjects: 768
Study 30010751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study 28119496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 125 mg of bosentan twice daily plus 10 μg of iloprost 4‐6 times/d
Number of subjects: 27
Study 28119496 — intervention group
Group type: COMPARATOR
Intervention: Bosentan monotherapy with 125 mg of bosentan twice daily
Number of subjects: 27
Study 28119496 — intervention group
Group type: COMPARATOR
Intervention: Iloprost monotherapy with 10 μg of iloprost 4‐6 times/d
Number of subjects: 27
Study 28119496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 27
Study 25676452 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference condition (learning and retrieving an alternative mock crime)
Number of subjects: 120
Study 25676452 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study 25676452 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-delay conditions
Number of subjects: 120
Study 25676452 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-interference manipulation
Number of subjects: 120
Study 23283501 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-lipid-tolerance tests (OLTTs)
Number of subjects: 51
Study 21914118 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlaminar (IL) epidural steroid injection
Number of subjects: 64
Study 21914118 — intervention group
Group type: COMPARATOR
Intervention: Transforaminal (TF) epidural steroid injection
Number of subjects: 64
Study 18640304 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital air leak system
Number of subjects: 100
Study 18640304 — intervention group
Group type: COMPARATOR
Intervention: Analogue air leak system
Number of subjects: 100
Study 16511340 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 60
Study 16511340 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 12971730 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal BCAA administration
Number of subjects: 12
Study 12971730 — intervention group
Group type: COMPARATOR
Intervention: Daytime BCAA administration
Number of subjects: 12
Study 10755543 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 1 g/day
Number of subjects: 176
Study 10755543 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g/day
Number of subjects: 176
Study 10755543 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA
Number of subjects: 176
Study 10755543 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 176
Study 9294478 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg days -1, 0, 1, 7, 8, and 9 of each cycle)
Number of subjects: 83
Study 9294478 — intervention group
Group type: COMPARATOR
Intervention: No methylprednisolone
Number of subjects: 83
Study 9294478 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 83
Study 8360006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline fiber only
Number of subjects: 8
Study 8360006 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing and tetracycline fibers
Number of subjects: 8
Study 8360006 — intervention group
Group type: EXPERIMENTAL
Intervention: Root planing only
Number of subjects: 8
Study 8360006 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (controls)
Number of subjects: 8
Study 3491907 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0
Study 3491907 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia
Number of subjects: 0
Study 30509634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) at 10°C
Number of subjects: 8
Study 30509634 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral Water Immersion (TWI) at 28°C
Number of subjects: 8
Study 28194688 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-initiated buprenorphine with 10-week continuation in primary care
Number of subjects: 290
Study 28194688 — intervention group
Group type: COMPARATOR
Intervention: Referral
Number of subjects: 290
Study 28194688 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 290
Study 28194688 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-initiated buprenorphine
Number of subjects: 290
Study 25425434 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ) 1,000 mg plus chloroquine (CQ) 600 mg base once daily for three days
Number of subjects: 467
Study 25425434 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine hydrochloride (MQ) 1,250 mg (split dose)
Number of subjects: 467
Study 25425434 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ) 500 mg plus chloroquine (CQ) 600 mg base once daily for three days
Number of subjects: 467
Study 25425434 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine hydrochloride (MQ)
Number of subjects: 467
Study 24349598 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisolone (2 mg/kg)
Number of subjects: 0
Study 24349598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20107293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies for PHN pain relief
Number of subjects: 0
Study 18390971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m² day 1 followed by 250 mg/m² weekly) plus Irinotecan (350 mg/m² every 3 weeks)
Number of subjects: 1298
Study 18390971 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan alone
Number of subjects: 1298
Study 18390971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus Irinotecan
Number of subjects: 1298
Study 16797948 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release metformin hydrochloride pellets (F-2, F-3)
Number of subjects: 12
Study 16797948 — intervention group
Group type: COMPARATOR
Intervention: Immediate release metformin tablet (Glucophage)
Number of subjects: 12
Study 14505991 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol ester-enriched vegetable oil (0.45 g/day as free sterol)
Number of subjects: 60
Study 14505991 — intervention group
Group type: COMPARATOR
Intervention: Control vegetable oil (0.04 g phytosterol as the major free sterol)
Number of subjects: 60
Study 10811340 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin (3 million units of alpha‐interferon three times weekly with 1000 mg of ribavirin daily)
Number of subjects: 29
Study 10811340 — intervention group
Group type: COMPARATOR
Intervention: Interferon and amantadine (3 million units of alpha‐interferon with 200 mg of amantadine daily)
Number of subjects: 29
Study 10811340 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin
Number of subjects: 29
Study 10811340 — intervention group
Group type: COMPARATOR
Intervention: Interferon and amantadine
Number of subjects: 29
Study 9023837 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea during pelvic radiotherapy
Number of subjects: 0
Study 9023837 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin-containing regimens followed by radiotherapy
Number of subjects: 0
Study 9023837 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 9023837 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy after radiotherapy
Number of subjects: 0
Study 7816256 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine 15 mg/kg administered 1 hour before dialysis
Number of subjects: 10
Study 7816256 — intervention group
Group type: COMPARATOR
Intervention: Desferrioxamine 15 mg/kg administered 44 hours before dialysis
Number of subjects: 10
Study 2897784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (300 mg, once daily at bedtime)
Number of subjects: 141
Study 2897784 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg, once daily at bedtime)
Number of subjects: 141
Study 28683941 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 117
Study 28683941 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 117
Study 26413958 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive harvesting techniques without periosteum elevation (group 1)
Number of subjects: 56
Study 26413958 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive harvesting techniques with periosteum elevation (group 2)
Number of subjects: 56
Study 23628620 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk DR3/DR4 genotype
Number of subjects: 1333
Study 23628620 — intervention group
Group type: EXPERIMENTAL
Intervention: Full model including HLA information and SNPs from CTLA4 and INS
Number of subjects: 1333
Study 23628620 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype information equivalent to typing four SNPs (DR3, DR4-DQB1*03:02, CTLA-4, and INS)
Number of subjects: 1333
Study 21337296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy plus resource activation (RFCBT)
Number of subjects: 52
Study 21337296 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT) alone
Number of subjects: 52
Study 19417872 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol lozenges (5 pieces/day, 2 g each) for 4 weeks
Number of subjects: 61
Study 19417872 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol lozenges (5 pieces/day, 2 g each) for 4 weeks
Number of subjects: 61
Study 18164917 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 171
Study 18164917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 171
Study 18164917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 15188351 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA (8 mg/kg body weight)
Number of subjects: 164
Study 15188351 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA (4 mg/kg body weight)
Number of subjects: 164
Study 15188351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 11490049 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus a reinforcement‐to‐change discussion group
Number of subjects: 99
Study 11490049 — intervention group
Group type: COMPARATOR
Intervention: Information only
Number of subjects: 99
Study 11490049 — intervention group
Group type: COMPARATOR
Intervention: Information plus an innocuous discussion group
Number of subjects: 99
Study 9731960 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirak Home Care Packs
Number of subjects: 0
Study 9731960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8521306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms.kg-1
Number of subjects: 42
Study 8521306 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 42
Study 2334454 — intervention group
Group type: EXPERIMENTAL
Intervention: ibopamine solution 1%
Number of subjects: 18
Study 2334454 — intervention group
Group type: COMPARATOR
Intervention: tropicamide solution 1%
Number of subjects: 18
Study 2334454 — intervention group
Group type: EXPERIMENTAL
Intervention: ibopamine solution 0.25% and 0.50%
Number of subjects: 18
Study 2334454 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 103404 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine iotroxate (3.6 g iodine)
Number of subjects: 195
Study 103404 — intervention group
Group type: COMPARATOR
Intervention: Meglumine iodoxamate (5.3 g iodine)
Number of subjects: 195
Study 103404 — intervention group
Group type: COMPARATOR
Intervention: Meglumine ioglycamate (5.3 g iodine)
Number of subjects: 195
Study 31387429 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) supplementation with pregabalin for 40 days
Number of subjects: 11
Study 31387429 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin alone
Number of subjects: 11
Study 31387429 — intervention group
Group type: COMPARATOR
Intervention: Placebo with pregabalin
Number of subjects: 11
Study 28774278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fun 'n healthy in Moreland! intervention
Number of subjects: 2965
Study 26153485 — intervention group
Group type: EXPERIMENTAL
Intervention: Melker 3.5 in contextualized scenario (CS)
Number of subjects: 65
Study 26153485 — intervention group
Group type: COMPARATOR
Intervention: Melker 3.5 in non-contextualized scenario (NCS)
Number of subjects: 65
Study 26153485 — intervention group
Group type: EXPERIMENTAL
Intervention: Melker 5.0 in contextualized scenario (CS)
Number of subjects: 65
Study 26153485 — intervention group
Group type: COMPARATOR
Intervention: Melker 5.0 in non-contextualized scenario (NCS)
Number of subjects: 65
Study 26153485 — intervention group
Group type: EXPERIMENTAL
Intervention: Portex 6.0 in contextualized scenario (CS)
Number of subjects: 65
Study 26153485 — intervention group
Group type: COMPARATOR
Intervention: Portex 6.0 in non-contextualized scenario (NCS)
Number of subjects: 65
Study 23316894 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-handed care
Number of subjects: 10